1. Home
  2. TKNO vs NKTR Comparison

TKNO vs NKTR Comparison

Compare TKNO & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alpha Teknova Inc.

TKNO

Alpha Teknova Inc.

N/A

Current Price

$6.94

Market Cap

268.1M

Sector

Health Care

ML Signal

N/A

Logo Nektar Therapeutics

NKTR

Nektar Therapeutics

N/A

Current Price

$67.17

Market Cap

2.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TKNO
NKTR
Founded
1996
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
268.1M
2.2B
IPO Year
2021
1996

Fundamental Metrics

Financial Performance
Metric
TKNO
NKTR
Price
$6.94
$67.17
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$146.67
AVG Volume (30 Days)
168.0K
511.4K
Earning Date
05-06-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
43.86
N/A
EPS
N/A
N/A
Revenue
$40,520,000.00
$307,711,000.00
Revenue This Year
$8.27
N/A
Revenue Next Year
$13.13
N/A
P/E Ratio
N/A
N/A
Revenue Growth
7.35
86.00
52 Week Low
$1.91
$33.40
52 Week High
$7.84
$109.00

Technical Indicators

Market Signals
Indicator
TKNO
NKTR
Relative Strength Index (RSI) 52.22 34.77
Support Level $4.87 $64.28
Resistance Level $7.66 $76.63
Average True Range (ATR) 0.36 2.75
MACD -0.11 -0.86
Stochastic Oscillator 43.51 7.41

Price Performance

Historical Comparison
TKNO
NKTR

About TKNO Alpha Teknova Inc.

Alpha Teknova Inc is a producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. Its offer two primary product categories: Lab Essentials and Clinical Solutions. It derives key revenue from the United States. The company offers three primary product types: (i) pre-poured media plates for cell growth and cloning; (ii) liquid microbial culture media and supplements for cellular expansion; and (iii) molecular biology reagents for sample manipulation, resuspension, and purification.

About NKTR Nektar Therapeutics

Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.

Share on Social Networks: